STATISTICS

Some useful facts about MRC Technology

• At the start of 2009 total licensing income generated by MRCT stood at over GBP £434m, one of the highest rates of return internationally.
• 12 drugs based on MRC IP have marketing approval, including Humira® and Herceptin®
• MRCT has been involved in 17 start-up companies, including UCB Celltech and CAT
• There are currently 11 active programs in the Drug Discovery Group
• Monies awarded by the Development Gap Fund total GBP£4.4m (US$8m) to March 2007
• More than 20 companies are licensed to sell MRC research reagents

10 Year Anniversary Statement

MRC licence income (from Annual Report 2008/09)
MRCT performance
  Year        Receipts (£k)
1998/99        2,853
1999/00        7,582
2000/01        17,946
2001/02        11,713
2002/03        14,181
2003/04        15,920
2004/05        22,005
2005/06        141,957
2006/07        64,769
2007/08        85,444
2008/09        54,980
Total           439,350

Note 1: The MRC’s licensing income in 2006/07 is comparable to that achieved by the highest-earning US Universities, as shown in the AUTM Licensing Survey; FY2007 (which covers activities relating to inventions in all fields not only the biomedical). See http://www.autm.net/Surveys.htm

Note 2: The “Higher Education – Business and Community Interaction Survey
2007-08” (which covers all UK HEIs) states that overall income from licensing was £45 million in 2007-08. In comparison, licensing income from MRC’s intramural programme for 2007/08 was £85.4 million, (1.89 times that of all UK universities combined). [see http://www.hefce.ac.uk/pubs/hefce/2009/09_23/ ]